ArticleNeoplasia (New York, N.Y.)2018
Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study.
Article in Neoplasia (New York, N.Y.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- A Systematic Review and Meta-analysis on the Occurrence of Biomarker Mutation in Colorectal Cancer among the Asian Population.BioMed research international · 2022Pooled it
- Fluorodeoxyglucose Metabolic Phenotypes Across Molecular Subgroups of Primary Colorectal Cancer: A Retrospective Three-Group Analysis.Journal of clinical medicine · 2026Article
- Clinical Impact of Baseline ctDNACancers · 2026Article
- Clinical and prognostic characteristics of metastatic colorectal cancer with minorOncology letters · 2025Article
- Current Status of Precision Medicine in Colorectal Cancer in Japan.International journal of molecular sciences · 2025Review
- Impact of early tumor shrinkage and depth of response in patients with BRAF V600E-mutant metastatic colorectal cancer.International journal of clinical oncology · 2025Article
- Article
- Development and validation of a multi-marker liquid bead array assay for the simultaneous detection ofHeliyon · 2024Article
- Article
- Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy.Nature communications · 2024Article
- Engineering Innovative Interfaces for Point-of-Care Diagnostics.Current opinion in colloid & interface science · 2023Review
- Clinical Validation of Plasma-Based Genotyping forJCO precision oncology · 2023Article
- The Impact of KRAS Status on the Required Surgical Margin Width for Colorectal Liver Metastasis Resection.Journal of clinical medicine · 2023Article
- Performance of IdyllaInternational journal of clinical oncology · 2022Article
- Colorectal carcinoma occurring via the adenoma-carcinoma pathway in patients with serrated polyposis syndrome.Journal of gastroenterology · 2022Article
- The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study.The oncologist · 2021Observational
- Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan.BMC cancer · 2021Article
- Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study.Therapeutic advances in medical oncology · 2021Article
- SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.Journal for immunotherapy of cancer · 2020Article
- Design and Evaluation of a Multiplexed Assay to Assess Human Immunogenicity Against Humira®.The AAPS journal · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Detection of RAS and BRAF mutations is essential to determine the optimal treatment strategy for metastatic colorectal cancer (CRC). We prospectively evaluated the MEBGEN RASKET-B KIT (RASKET-B), a novel multiplex kit, simultaneously detecting 48 types of RAS mutations and the BRAF V600E mutation using Luminex xMAP technology. The aim was to obtain market approval for RASKET-B as an in vitro diagnostic (IVD) option in Japan. Genomic DNA was extracted from 302 formalin-fixed paraffin-embedded tissues obtained from CRC patients. The primary endpoints were the concordance rate (CR) between the results from RASKET-B and the previously approved IVD kit (RASKET) for RAS mutations, and CR between the results from RASKET-B and direct sequencing (DS) for BRAF mutations. The secondary endpoints included the CR between RASKET-B and DS for RAS mutations and between RASKET-B and the pyrosequencing (PYRO) for the BRAF V600E mutation. Among the 302 samples, 142 RAS mutations (47%) and 18 BRAF V600E mutations (6.0%) were detected by RASKET-B. All mutations detected in the recruited patients were mutually exclusive. Both RAS and BRAF mutation rates were statistically higher in right-sided than left-sided CRC. The CR between RASKET-B and RASKET for RAS gene and RASKET-B and DS for BRAF V600E mutation was 100% for both (95% CI: 99%-100%). The results from RASKET-B were also highly concordant with DS for RAS (97.4%) and with PYRO for the BRAF (V600E) gene (99.7%). RASKET-B thus provides rapid, precise, and simultaneous detection of RAS and BRAF mutations in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.